UCB (OTCMKTS:UCBJF) Stock Price Down 7.4% – Should You Sell?

UCB SA (OTCMKTS:UCBJF) shares fell 7.4% on Tuesday . The stock traded as low as $281.11 and last traded at $297.1875. 133 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 765 shares. The stock had previously closed at $321.05.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on UCBJF. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research report on Monday, February 16th. Wolfe Research began coverage on shares of UCB in a research report on Monday, February 23rd. They issued an “outperform” rating on the stock. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy”.

UCB Stock Performance

The business’s 50-day moving average is $295.52 and its 200 day moving average is $299.47. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.